QVT score, a radiomic biomarker of vascular complexity, enables prognostication and monitoring of NSCLC immunotherapy
QVT score is a novel, biologically interpretable imaging biomarker that quantifies vascular complexity. It enables automated, non-invasive prediction and monitoring of ICI outcomes by capturing treatment-induced vascular remodeling. Integrating QVT score into clinical decision-making and drug development can address critical gaps in precision oncology.
Authors
- Trevor Cheung
- Liam Il‐Young Chung (ORCID: https://orcid.org/0000-0001-6541-793X)
- Rhea Chitalia (ORCID: https://orcid.org/0000-0001-7880-930X)
- Amogh Hiremath
- Haseok Kim
- Kwang Chae Young
- Nathaniel Braman (ORCID: https://orcid.org/0000-0001-5603-0821)
- Diego Cantor
- S. Lee (ORCID: https://orcid.org/0009-0003-8674-1132)
- Rushil Nagabhushan
- Haojia Li
- Vamsidhar Velcheti
- David Levy
- Pushkar Mutha
- Yuchan Kim
- Amit Gupta
- Jeeyeon Lee
- Trishan Arul
- Omid Haji-Maghsoudi
- Anant Madabhushi
- Kai Zhang
Institutions
- Northwestern University (US)
- University of Waterloo (CA)
- University Hospitals of Cleveland (US)
- Ohio Department of Health (US)
- Jacksonville College (US)
- The Wallace H. Coulter Department of Biomedical Engineering (US)
- University Hospitals Cleveland Medical Center (US)
- Mayo Clinic in Florida (US)
- University School (US)
- Case Western Reserve University (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1136/jitc-2025-013391
- Citations
- 1
- Primary Topic
- Radiomics and Machine Learning in Medical Imaging
- Type
- article
- Field-Weighted Citation Impact
- 31.92
Funders
- National Science Foundation
- U.S. Department of Defense
- U.S. Department of Veterans Affairs
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Regeneron Pharmaceuticals
- Novocure
- Eisai
- National Institutes of Health
- Genentech
- Foundation Medicine
- National Cancer Institute